Literature DB >> 1987108

Relations between fundus appearance and function. Eyes whose fellow eye has exudative age-related macular degeneration.

A Eisner1, V D Stoumbos, M L Klein, S A Fleming.   

Abstract

Foveal visual function was compared with fundus appearance for 41 eyes that had good acuity but whose fellow eye had exudative age-related macular degeneration (AMD). The visual functions tested were among those reported to be compromised by AMD. They included: (1) dark adaptation, (2) absolute sensitivity, (3) S cone-mediated sensitivity, and (4) color matching. The fundus features used to evaluate the risk of developing exudative AMD included: (1) drusen confluence, (2) drusen size, and (3) focal hyperpigmentation. For the group of eyes defined by the presence of one or more high-risk fundus characteristics, all visual functions were compromised significantly. In particular, all 21 eyes with abnormally slow rates of dark adaptation had high-risk fundi, and all 16 eyes with abnormal color matching (ie, a small effect of test area on the color match or rejection of all potential color matches) had high-risk fundi. Conversely, 30 of the 32 eyes with high-risk fundi had abnormally slow rates of dark adaptation or abnormal color matching. In addition, reduced acuity in the fellow exudative eye was associated significantly with a high-risk fundus in the nonexudative eye.

Entities:  

Mesh:

Year:  1991        PMID: 1987108

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  24 in total

1.  Identification of lesion components that influence visual function in age related macular degeneration.

Authors:  R Hogg; E Curry; A Muldrew; J Winder; M Stevenson; M McClure; U Chakravarthy
Journal:  Br J Ophthalmol       Date:  2003-05       Impact factor: 4.638

2.  Improved contrast of subretinal structures using polarization analysis.

Authors:  Stephen A Burns; Ann E Elsner; Mariane B Mellem-Kairala; Ruthanne B Simmons
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-09       Impact factor: 4.799

3.  Disclosing disease mechanisms with a spatio-temporal summation paradigm.

Authors:  Andrew J Zele; Rebecca K O'Loughlin; Robyn H Guymer; Algis J Vingrys
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-12       Impact factor: 3.117

4.  Microperimetry and fundus autofluorescence in patients with early age-related macular degeneration.

Authors:  Edoardo Midena; Stela Vujosevic; Enrica Convento; Antonio Manfre'; Fabiano Cavarzeran; Elisabetta Pilotto
Journal:  Br J Ophthalmol       Date:  2007-05-15       Impact factor: 4.638

5.  The effect of pre-adapting light intensity on dark adaptation in early age-related macular degeneration.

Authors:  Allannah J Gaffney; Alison M Binns; Tom H Margrain
Journal:  Doc Ophthalmol       Date:  2013-07-17       Impact factor: 2.379

6.  Measurement of cone dark adaptation: a comparison of four psychophysical methods.

Authors:  Allannah J Gaffney; Alison M Binns; Tom H Margrain
Journal:  Doc Ophthalmol       Date:  2013-11-22       Impact factor: 2.379

7.  Spatial distribution of macular birefringence associated with the Henle fibers.

Authors:  Ann E Elsner; Anke Weber; Michael C Cheney; Dean A Vannasdale
Journal:  Vision Res       Date:  2008-06-16       Impact factor: 1.886

8.  Henle fiber layer phase retardation changes associated with age-related macular degeneration.

Authors:  Dean A VanNasdale; Ann E Elsner; Todd D Peabody; Kimberly D Kohne; Victor E Malinovsky; Bryan P Haggerty; Anke Weber; Christopher A Clark; Stephen A Burns
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-12-18       Impact factor: 4.799

Review 9.  The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD.

Authors:  Sayantan Datta; Marisol Cano; Katayoon Ebrahimi; Lei Wang; James T Handa
Journal:  Prog Retin Eye Res       Date:  2017-03-20       Impact factor: 21.198

10.  Colour vision testing as an aid to diagnosis and management of age related maculopathy.

Authors:  G B Arden; J E Wolf
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.